Piotr Rutkowski, MD, PhD

Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland

Piotr Rutkowski is Professor of Surgical Oncology at the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology in Warsaw, Poland. 

Dr Rutkowski is the current Head of the Department of Soft Tissue/Bone Sarcoma and Melanoma, the Plenipotentiary Director of Institute for Clinical Trials at the Maria Sklodowska-Curie Memorial Cancer Center as well as the President of Scientific Council of Maria Sklodowska-Curie Memorial Cancer Center. He has participated in several investigator-driven trials in melanoma and sarcoma. He is also Coordinator of the Polish Clinical GIST Registry, and a reviewer for several international scientific journals, as well as a member of the Editorial Board of Annals of Surgical Oncology and European Journal of Surgical Oncology. 

Dr Rutkowski is an active member of the EORTC Soft Tissue and Bone Sarcoma Group, where he chaired the Local Treatment Subcommittee and the Membership Committee of the EORTC Board. He is also an active member of the EORTC Melanoma Group and the Global Melanoma Task Force. He is a member of several Polish and international scientific societies (Board member and President of Polish Society Surgical Oncology and Ex-member of the Board of Directors of the Connective Tissue Oncology Society). Dr Rutkowski has authored or co-authored over 120 scientific papers in Polish and international journals (with an impact factor of above 1200, index-H: 32, citation index >4000), and is co-author of national and international recommendations for sarcoma and melanoma. He is working very closely with national patient advocacy groups for GIST and sarcoma and he is Chairman of the Melanoma Academy in Poland. Main scientific activities: melanoma research (sentinel node biopsy issues; adjuvant therapy; detection of submicroscopic disease and circulating prognostic markers), GIST (molecular aspects of treatment of advanced disease and mechanisms of resistance to targeted therapy), sarcoma (multimodal treatment and molecular prognostic factors).